References
1. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation, 2021. URL: https://diabetesatlas.org/
2. World Health Organization Diabetes Fact Sheets, 2022. URL: https://www.who.int/news-room/fact-sheets/detail/diabetes
3. Blonde L., Stenlöf K., Fung A., Xie J., Canovatchel W., Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016; 128 (4): 371–80. DOI: https://doi.org/10.1080/00325481.2016.1169894
4. Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Bonaca M.P., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393 (10 166): 31–9. DOI: https://doi.org/10.1016/S-0140-6736(18)32590-X
5. Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380 (4): 347–57. DOI: https://doi.org/10.1056/NEJMoa1812389
6. Wilding J., Bailey C., Rigney U., Blak B. Glycated hemoglobin, body weight and blood pressure in type 2 diabetes patients initiating dapagliflozin treatment in primary care: a retrospective study. Diabetes Ther. 2016; 7: 695–711. DOI: https://doi.org/10.1007/s13300-016-0193-8
7. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., et al.; on behalf of the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–28. DOI: https://doi.org/10.1056/NEJMoa1504720
8. Mikhail N. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes. 2014; 5 (6): 854–9. PMID: 25512787 DOI: https://doi.org/10.4239/wjd.v5.i6.854
9. Report CMaMW. Prevalence of overweight and obesity among adults with diagnosed diabetes – United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep. 2004; 53 (45): 1066–8. URL: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5345a2.htm
10. Harvard Medical School. Healthy Eating Plate dishes out sound diet advice: more specific than MyPlate, it pinpoints the healthiest food choices. Harv Heart Lett. 2011; 22 (4): 6. URL: https://www.health.harvard.edu/heart-health/healthy-eating-plate-dishes-out-sound-diet-advice
11. Stefan N., Stumvoll M. Adiponectin--its role in metabolism and beyond. Horm Metab Res. 2002; 34 (9): 469–74. DOI: https://doi.org/10.2302/kjm.60.1
12. Kobayashi M., Deguchi Y., Nozaki Y., et al. Contribution of PGC-1a to obesity- and caloric restriction-related physiological changes in white adipose tissue. Int J Mol Sci. 2021; 22 (11): 6025. DOI: https://doi.org/10.3390/ijms22116025
13. Bao J.F., She Q.Y., Hu P.P., Jia N., Li A. Irisin, a fascinating field in our times. Trends Endocrinol Metab. 2022; 33 (9): 601–13. DOI: https://doi.org/10.1016/j.tem.2022.06.003
14. Ciaraldi T.P., Ryan A.J., Mudaliar S.R., Henry R.R. Altered myokine secretion is an intrinsic property of skeletal muscle in type 2 diabetes. PLoS One. 2016; 11 (7): e0158209. DOI: https://doi.org/10.1371/journal.pone.0158209
15. Schmidt F.M., Weschenfelder J., Sander C., et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS One. 2015; 10 (3): e0121971. DOI: https://doi.org/10.1371/journal.pone.0121971
16. Tsalamandris S., Antonopoulos A.S., Oikonomou E., et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol. 2019; 14 (1): 50–9. DOI: https://doi.org/10.15420/ecr.2018.33.1
17. Rus H.G., Vlaicu R., Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996; 127 (2): 263–71. DOI: https://doi.org/10.1016/S-0021-9150(96)05968-0
18. Eltoft A., Arntzen K.A., Wilsgaard T., Mathiesen E.B., Johnsen S.H. Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: the Tromso Study. Atherosclerosis. 2018; 271: 1–8. DOI: https://doi.org/10.1016/j.atherosclerosis.2018.02.005
19. Mohammed Saeed W., Nasser Binjawhar D. Association of serum leptin and adiponectin concentrations with type 2 diabetes biomarkers and complications among Saudi women. Diabetes Metab Syndr Obes. 2023; 16: 2129–40. DOI: https://doi.org/10.2147/DMSO.S405476
20. Zaccardi F., Webb D.R., Htike Z.Z., Youssef D., Khunti K., Davies M.J. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab. 2016; 18 (8): 783–94. DOI: https://doi.org/10.1111/dom.12670
21. Scheerer M.F., Rist R., Proske O., Meng A., Kostev K. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes Metab Syndr Obes. 2016; 9: 337–45. DOI: https://doi.org/10.2147/DMSO.S-116243
22. Bolinder J., Ljunggren Ö., Kullberg J., Johansson L., Wilding J., Langkilde A.M., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97 (3): 1020–31. DOI: https://doi.org/10.1210/jc.2011-2260
23. Blonde L., Stenlöf K., Fung A., Xie J., Canovatchel W., Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016; 128 (4): 371–80. DOI: https://doi.org/10.1080/00325481.2016.1169894
24. Bolinder J., Ljunggren Ö., Kullberg J., Johansson L., Wilding J., Langkilde A.M., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97 (3): 1020–31. DOI: https://doi.org/10.1210/jc.2011-2260
25. Tobita H., Sato S., Miyake T., Ishihara S., Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp. 2017; 87: 13–9. DOI: https://doi.org/10.1016/j.curtheres.2017.07.002
26. Yamakage H., Tanaka M., Inoue T., Odori S., Kusakabe T., Satoh-Asahara N. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: a randomized, controlled trial. J Diabetes Investig. 2020; 11 (3): 653–61. DOI: https://doi.org/10.1111/jdi.13179
27. Merovci S.-H.C., Daniele G., Eldor R., Fiorentino T.V., Tripathy D., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014; 124 (2): 509–14. DOI: https://doi.org/10.1172/JCI70704
28. Obata K.N., Kubota T., Iwamoto M., Sato H., Sakurai Y., Takamoto I., et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology. 2016; 157 (3): 1029–42. DOI: https://doi.org/10.1210/en.2015-1588
29. Sugiyama S., Jinnouchi H., Kurinami N., Hieshima K., Yoshida A., Jinnouchi K., et al. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb. 2018; 25 (6): 467–76. DOI: https://doi.org/10.5551/jat.40873
30. Bell D.S., Patil H.R., O’Keefe J.H. Divergent effects of various diabetes drugs on cardiovascular prognosis. Rev Cardiovasc Med. 2013; 14 (2-4): e107-22. DOI: https://doi.org/10.3909/ricm0671
31. Zaccardi F., Webb D.R., Htike Z.Z., Youssef D., Khunti K., Davies M.J. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab. 2016; 18 (8): 783–94. DOI: https://doi.org/10.1111/dom.12670